Open-label, Dose-finding Study to Determine Antibody Response to G17DT Treatment in Patients With Gastric Cancer.

Inclusion Criteria: * Histologically confirmed UICC Stage I, II or III gastric adenocarcinoma. Must have had a macroscopically curative resection for gastric cancer with absence of metastatic disease at the time of entry to the trial * Male or female and over 18 years of age * Must have a life expectancy of at least three months * World Health Organization Performance Status of 0 to 1 * Given written conformed consent Exclusion Criteria: * Gastric surgery within four weeks of baseline (week 0) or gastric surgery anticipated in the period of the study * History of other malignant disease within the previous five years, except non-melanomatous skin cancer or in situ carcinoma of the uterine cervix * Previous use within the last four weeks, concomitant use or anticipated use in the period of the study, of any anti-cancer therapies * Concomitant use of immunosuppressants, including systemic (i.e. oral or injected) corticosteroids * Females who pregnant, planning to become pregnant or lactating * Taking part in another study involving an investigational or licensed drug or device in the three months preceding enrollment or during this study * Previously received G17DT treatment * Haemoglobin (Hb) \< 10.0 g/dL White blood cell count (WBC) \< 4.0 x 10\^9/L Platelets \< 100 x 10\^9/L